Caris Life Sciences Reports Q3 2026 Financial Results

Caris Life Sciences reported Q3 2026 revenue of $275.4 million, up 27% year over year and above the $255.4 million FactSet consensus; EPS was $0.05 versus expectations of $0.03. Revenue growth reflected clinical case volume rising about 21% and improved average selling prices. The company raised its 2026 revenue guidance to $1.04 billion–$1.05 billion and reported net income of $15.3 million, adjusted EBITDA of $44.4 million, and operating cash flow of negative $22.2 million for the quarter.